Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | RAC2 |
| Gene Name: | RAC2 |
| Protein Full Name: | Ras-related C3 botulinum toxin substrate 2 |
| Alias: | EN-7; GX; p21-Rac2; ras-related C3 botulinum toxin substrate 2; small G protein |
| Mass (Da): | 21429 |
| Number AA: | 192 |
| UniProt ID: | P15153 |
| Locus ID: | 5880 |
| COSMIC ID: | RAC2 |
| Gene location on chromosome: | 22q13.1 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | UNCLEAR |
| Number of cancer specimens: | 20217 |
| Percent of cancer specimens with mutations: | 0.23 |
| Normal role description: | Plasma membrane-associated small GTPase which cycles between an active GTP-bound and inactive GDP-bound state. In active state binds to a variety of effector proteins to regulate cellular responses, such as secretory processes, phagocytose of apoptotic cells and epithelial cell polarization. Augments the production of reactive oxygen species (ROS) by NADPH oxidase. Missense mutations have been found in skin and larynx tumors. Overexpression of Rac2 has been found in 1/10 astrocytomas and 1/8 meningiomas, while decreased expression has been found in 15 of 26 brain tumors: 8/10 astrocytomas, 2/8 meningiomas, and 5/8 pituitary adenomas. |
| Commentary on involvement of protein in cancer: | Plasma membrane-associated small GTPase which cycles between an active GTP-bound and inactive GDP-bound state. In active state binds to a variety of effector proteins to regulate cellular responses, such as secretory processes, phagocytose of apoptotic cells and epithelial cell polarization. Augments the production of reactive oxygen species (ROS) by NADPH oxidase. |